1-tert-butyl-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile | 858340-88-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 1-tert-butyl-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile
• 英文别名: 1H-Pyrrolo[2,3-b]pyridine-3-carbonitrile, 1-(1,1-dimethylethyl)-5-nitro-；1-tert-butyl-5-nitropyrrolo[2,3-b]pyridine-3-carbonitrile
• CAS: 858340-88-2
• 化学式: C₁₂H₁₂N₄O₂
• 分子量: 244.253
• InChiKey: YUXIWHIEGPTTDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  87.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-tert-butyl-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 以95%的产率得到1-tert-butyl-5-amino-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile
  参考文献：
  名称：

  Design, synthesis and transformation of some heteroannulated 3-aminopyridines—purine isosteres with exocyclic nitrogen atom

  摘要：

  The synthesis of 1-deazapurines and isosteres bearing the exocyclic nitrogen atom at position-1 was developed basing on the formal [3+3]-cyclization reaction of nitro-malonaldehyde with the set of electron-excessive aminoheterocycles. Through the functionalization of the purine-like scaffolds synthesized the diversity of compounds furnished in the possition-1 with aryl, alkinyl, and vinyl rests, were obtained. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.11.026
• 作为产物：
  描述：

  5-氨基-1-叔丁基-1H-吡咯-3-甲腈 、 nitromalondialdehyde sodium salt 在 三甲基氯硅烷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-tert-butyl-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile
  参考文献：
  名称：

  融合的3-硝基吡啶和其他硝基取代的杂芳烃的区域选择性直接芳构化：硝基基团作为指导基团的多用途性质。

  摘要：

  我们报道了一系列融合的3-硝基吡啶的Pd和Ni催化，导向和区域选择性的CH芳基化反应。此处描述的方法是用于药物样融合吡啶的化学功能化的简便工具。讨论了反应的范围和局限性，硝基的化学势以及可能的反应机理。

  DOI：

  10.1002/cctc.201402715

文献信息

• [EN] PYRROLO[2,3-b] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM<br/>[FR] DERIVES PYRROLO[2,3-B]PYRIDINE AGISSANT COMME INHIBITEURS DES KINASES, PROCEDE POUR LEUR ELABORATION, ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
  申请人：PHARMACIA ITALIA SPA

  公开号：WO2005063747A1

  公开（公告）日：2005-07-14

  Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenrative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

  本发明揭示了属于吡咯并[2,3-b]吡啶衍生物或其药用可接受盐的化合物，以及它们的制备过程和包含它们的药物组合物；这些化合物对治疗由蛋白激酶活性改变引起和/或相关的疾病具有用处，如癌症、细胞增殖异常、阿尔茨海默病、病毒感染、自身免疫疾病和神经退行性疾病；还揭示了一种在SPS条件下制备本发明化合物的方法，以及包含多种这些化合物的化学文库。
• Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
  申请人：Salom Barbara

  公开号：US20050209269A1

  公开（公告）日：2005-09-22

  Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

  本发明公开了吡咯并[2,3-b]吡啶衍生物或其药学上可接受的盐、它们的制备方法以及包含它们的制药组合物；这些化合物在治疗由改变的蛋白激酶活性引起和/或与之相关的疾病方面具有用途，如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫性疾病和神经退行性疾病；还公开了一种在SPS条件下制备本发明化合物的方法以及包含多个化合物的化学库。
• Pyrrolo[2,3-B]pyridine derivatives active as kinase inhibitors
  申请人：Pfizer Italia S.r.l.

  公开号：US07888508B2

  公开（公告）日：2011-02-15

  Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

  本发明涉及吡咯[2,3-b]吡啶衍生物或其药学上可接受的盐，其制备方法以及包含它们的制药组合物；这些化合物可用于治疗由改变的蛋白激酶活性引起和/或与之相关的疾病，如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫性疾病和神经退行性疾病。本发明还公开了一种在SPS条件下制备本发明化合物的方法以及包含多种化合物的化学文库。
• Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors
  申请人：Pfizer Italia S.r.l.

  公开号：US08198298B2

  公开（公告）日：2012-06-12

  Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

  本发明公开了吡咯并[2,3-b]吡啶衍生物或其药学上可接受的盐，其制备方法以及包含它们的制药组合物。这些化合物在治疗由改变的蛋白激酶活性引起和/或相关的疾病方面具有用处，如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫疾病和神经退行性疾病；本发明还公开了在SPS条件下制备本发明化合物的方法和包含其中多种化合物的化学文库。
• PYRROLE[2,3-B]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS
  申请人：Salom Barbara

  公开号：US20110136857A1

  公开（公告）日：2011-06-09

  Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

  本发明公开了吡咯并[2,3-b]吡啶衍生物化合物或其药学上可接受的盐、其制备方法以及包含它们的制药组合物；这些化合物可用于治疗由改变的蛋白激酶活性引起和/或相关的疾病，如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫疾病和神经退行性疾病；本发明还公开了一种在SPS条件下制备本发明化合物以及包含多种化合物的化学文库的方法。